Regeneron Pharmaceuticals Inc
NASDAQ: REGN
$759.11
-$23.40 (-3.0%)
Real Time Data Delayed 15 Min.
REGN Articles
In a new report, the Credit Suisse team says large cap biotech is cheaper than the S&P 500 on 2016 and 2017 numbers. Here are the top biotech names rated Outperform at Credit Suisse.
Published:
courtesy of Morgan StanleyLike many of its Wall Street peers, the brutal sell-off in the biotechnology space has Morgan Stanley taking a closer look at the top names. The firm initiated coverage of...
Published:
For the second time in less than a month, the biotechnology sector got whacked when once again, chatter coming from the halls of Congress hit the sector hard. This may be a perfect entry point for...
Published:
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Monday, March 17, 2014. The include Baker Hughes, Cameron, Cisco Systems, Facebook and VeriSign.
Published:
The chief strategist at Piper Jaffray released his report for March. It details how the second and third quarters typically behave in the mid-term years after a solid first quarter. Here are the top...
Published:
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Thursday, February 13, 2014. They include Angie's List, Itron, NVIDIA, Regeneron and Sempra...
Published:
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Wednesday, February 12, 2014. They include Amazon, Control4, Ocwen Financial, Sprint and Veeco...
Published:
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Wednesday, January 15.
Published:
Baird offers an eclectic and interesting list for investors. A top regional firm, it tends to dig a little deeper, looking for ideas with not only growth potential, but catalysts. The usual big cap...
Published:
courtesy of Apple Inc.Like most firms that we cover on Wall Street, Piper Jaffray has updated its top names to buy for 2014, and the firm has an extensive market commentary to go along with the...
Published:
ThinkstockCredit Suisse is out and pounding the table that biotechnology cannot be ignored in 2014. Biotech has been the top-performing sector for the past three years, with year-to-date performance...
Published:
ThinkstockAny time investors look for companies growing sales the most, one area that almost always stands out is the up and coming biotech stocks. After all, sales can grow from close to nothing...
Published:
ThinkstockThe UBS proprietary institutional flow data indicates that hedge funds are increasing exposure to financials and decreasing exposure to health care. Given that health care has outperformed...
Published:
Last Updated:
ThinkstockThe field of pharmaceuticals is very well established and often is considered to be a very defensive sector. As such, investors flock to the drug sector in times of uncertainty. But what...
Published:
ThinkstockInvestors make big money in biotechnology stocks when they focus on areas that cut across a wide swath of the population. From obesity to food allergies to prostate cancer, the top...
Published:
Last Updated: